Johnson & Johnson stock: CAPLYTA filing seeks bipolar mania approval
Published on 11/20/2026 at 13:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCAPLYTA filing advances regulatory path
- Johnson & Johnson submitted an application seeking approval of CAPLYTA for manic or mixed episodes associated with bipolar I disorder.
- Two pivotal Phase 3 studies showed significant symptom improvement versus placebo as early as Day 3 and sustained improvement through Week 3.
- If approved, bipolar mania would become CAPLYTA's fifth approved adult use.
On November 19, 2026, Johnson & Johnson said it submitted a supplemental New Drug Application to the U.S. Food and Drug Administration seeking approval of CAPLYTA, or lumateperone, for manic or mixed episodes associated with bipolar I disorder in adults.
Johnson & Johnson stock traded at 247.10 euros on Lang & Schwarz at 13:29 CET on Friday, November 20, 2026, 2.11 percent above the Xetra close of Thursday, November 19.
Phase 3 evidence supports submission
The application is based on two pivotal, randomized, double-blind, placebo-controlled Phase 3 studies, identified as Study 451 and Study 452. Participants received once-daily CAPLYTA 42 mg or placebo for three weeks. The company said both studies met their primary and key secondary endpoints, with significant improvement in manic symptoms and overall illness severity compared with placebo.
Johnson & Johnson said symptom improvement emerged as early as Day 3, after two days of treatment, and continued through Week 3. The company also described CAPLYTA as well tolerated, with low discontinuation rates and a safety profile consistent with earlier studies. John C. Reed, executive vice president for Innovative Medicine Research and Development, said the results showed the treatment's potential to combine rapid symptom improvement with tolerability.
Potential fifth adult use
CAPLYTA is already approved for depressive episodes associated with bipolar I or bipolar II disorder, both as a standalone treatment and alongside lithium or valproate. It is also approved for schizophrenia and as an adjunctive treatment for major depressive disorder. Bipolar mania would be a new use if the FDA grants approval, making it the product's fifth approved adult indication.
For investors, the filing extends the potential commercial reach of a marketed medicine while shifting the next major milestone to the regulatory review. The submission itself is not an approval, and future commercial contribution would depend on the FDA decision and adoption in clinical practice.
Johnson & Johnson stock
- Company: Johnson & Johnson
- ISIN: US4781601046
- Ticker: JNJ
- Primary exchange: NYSE
- Lang & Schwarz quote: 247.10 euros on November 20, 2026, at 13:29 CET
- Xetra close: 242.00 euros on November 19, 2026
- Daily difference: 2.11 percent
- Event: Supplemental FDA application for CAPLYTA in bipolar mania
In the broader market, investors can follow the S&P 500.
